{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T17:07:47Z","timestamp":1784999267374,"version":"3.55.0"},"reference-count":24,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T00:00:00Z","timestamp":1650240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Recently, cytoreductive prostatectomy for metastatic prostate cancer (mPCa) has been associated with improved oncological outcomes. This study was aimed at evaluating whether robot-assisted radical prostatectomy (RARP) as a form of cytoreductive prostatectomy can improve oncological outcomes in patients with mPCa. We conducted a retrospective study of twelve patients with mPCa who had undergone neoadjuvant therapy followed by RARP. The endpoints were biochemical recurrence-free survival, treatment-free survival, and de novo metastasis-free survival. At the end of the follow-up period, none of the enrolled patients had died from PCa. The 1- and 2-year biochemical recurrence-free survival rates were 83.3% and 66.7%, respectively, and treatment-free survival rates were 75.0% and 56.3%, respectively. One patient developed de novo bone metastases 6.4 months postoperatively, and castration-resistant prostate cancer 8.9 months postoperatively. After RARP, the median duration of recovery of urinary continence was 5.2 months. One patient had severe incontinence (&gt;2 pads\/day) 24 months postoperatively. RARP may be a treatment option in patients with mPCa who have achieved a serum prostate-specific antigen level &lt; 0.2 ng\/mL, and present without new lesions on imaging.<\/jats:p>","DOI":"10.3390\/curroncol29040233","type":"journal-article","created":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T22:04:02Z","timestamp":1650319442000},"page":"2864-2870","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Robot-Assisted Radical Prostatectomy for Potential Cancer Control in Patients with Metastatic Prostate Cancer"],"prefix":"10.3390","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2774-925X","authenticated-orcid":false,"given":"Kimiaki","family":"Takagi","sequence":"first","affiliation":[{"name":"Department of Urology, Daiyukai Daiichi Hospital, Ichinomiya 4918551, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7269-2462","authenticated-orcid":false,"given":"Makoto","family":"Kawase","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, Gifu University, Gifu 5011194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4932-0497","authenticated-orcid":false,"given":"Daiki","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, Gifu University, Gifu 5011194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Kawase","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, Gifu University, Gifu 5011194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Takai","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, Gifu University, Gifu 5011194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0362-8624","authenticated-orcid":false,"given":"Koji","family":"Iinuma","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, Gifu University, Gifu 5011194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Nakane","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, Gifu University, Gifu 5011194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyasu","family":"Hagiwara","sequence":"additional","affiliation":[{"name":"Department of Urology, Matsunami General Hospital, Gifu 5016062, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Urology, Tokai Central Hospital, Kakamigahara 5048601, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Tomioka","sequence":"additional","affiliation":[{"name":"Department of Urology, Japanese Red Cross Takayama Hospital, Takayama 5068550, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2980-127X","authenticated-orcid":false,"given":"Takuya","family":"Koie","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, Gifu University, Gifu 5011194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_2","unstructured":"Prostate Cancer (2022, March 12). NCCN Guidelines\u00ae 2022. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","article-title":"EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer","volume":"79","author":"Cornford","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.eururo.2014.09.032","article-title":"Survival with Newly Diagnosed Metastatic Prostate Cancer in the \u201cDocetaxel Era\u201d: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK\/06\/019)","volume":"67","author":"James","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.eururo.2013.11.012","article-title":"Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study","volume":"65","author":"Culp","year":"2014","journal-title":"Eur. Urol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.juro.2015.02.084","article-title":"Radical Prostatectomy or External Beam Radiation Therapy vs No Local Therapy for Survival Benefit in Metastatic Prostate Cancer: A SEER-Medicare Analysis","volume":"194","author":"Satkunasivam","year":"2015","journal-title":"J. Urol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/S0022-5347(05)64562-4","article-title":"Impact of previous local treatment for prostate cancer on subsequent metastatic disease","volume":"168","author":"Thompson","year":"2002","journal-title":"J. Urol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/MOU.0000000000000444","article-title":"Radiation therapy to the primary in metastatic prostate cancer: Palliation only or altering tumor biology?","volume":"27","author":"Blanchard","year":"2017","journal-title":"Curr. Opin. Urol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1756-8722-5-34","article-title":"Cytoreduction surgery reduces systemic myeloid suppressor cell populations and restores intratumoral immunotherapy effectiveness","volume":"5","author":"Predina","year":"2012","journal-title":"J. Hematol. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3322\/caac.21391","article-title":"Prostate cancer\u2014major changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Buyyounouski","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/SLA.0b013e3181b13ca2","article-title":"The Clavien-Dindo classification of surgical complications: Five-year experience","volume":"250","author":"Clavien","year":"2009","journal-title":"Ann. Surg."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","article-title":"The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System","volume":"40","author":"Epstein","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.urology.2017.02.051","article-title":"Cytoreductive Prostatectomy for Metastatic Prostate Cancer: First Lessons Learned from the Multicentric Prospective Local Treatment of Metastatic Prostate Cancer (LoMP) Trial","volume":"106","author":"Poelaert","year":"2017","journal-title":"Urology"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Buelens, S., Poelaert, F., Claeys, T., De Bleser, E., Dhondt, B., Verla, W., Ost, P., Rappe, B., De Troyer, B., and Verbaeys, C. (2021). Multicentre, prospective study on local treatment of metastatic prostate cancer (LoMP study). BJU Int., in press.","DOI":"10.1111\/bju.15553"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.juro.2014.09.089","article-title":"Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: Results of a feasibility and case-control study","volume":"193","author":"Heidenreich","year":"2015","journal-title":"J. Urol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"E250","DOI":"10.1111\/bju.12169","article-title":"Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer","volume":"112","author":"Won","year":"2013","journal-title":"BJU Int."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.1200\/JCO.2006.06.4246","article-title":"Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: Data from Southwest Oncology Group Trial 9346 (INT-0162)","volume":"24","author":"Hussain","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.eururo.2016.04.031","article-title":"The Impact of Local Treatment on Overall Survival in Patients with Metastatic Prostate Cancer on Diagnosis: A National Cancer Data Base Analysis","volume":"72","author":"Dalela","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.cell.2009.11.025","article-title":"Tumor self-seeding by circulating cancer cells","volume":"139","author":"Kim","year":"2009","journal-title":"Cell"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/nature04186","article-title":"VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche","volume":"438","author":"Kaplan","year":"2005","journal-title":"Nature"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.cell.2008.04.045","article-title":"Systemic endocrine instigation of indolent tumor growth requires osteopontin","volume":"133","author":"McAllister","year":"2008","journal-title":"Cell"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00345-020-03296-8","article-title":"Metastatic hormone sensitive prostate cancer: Local treatment strategies","volume":"39","author":"Walz","year":"2021","journal-title":"World J. Urol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.eururo.2018.07.006","article-title":"Comparison of Perioperative Outcomes Between Cytoreductive Radical Prostatectomy and Radical Prostatectomy for Nonmetastatic Prostate Cancer","volume":"74","author":"Preisser","year":"2018","journal-title":"Eur. Urol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/4\/233\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:55:57Z","timestamp":1760136957000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/4\/233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,18]]},"references-count":24,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["curroncol29040233"],"URL":"https:\/\/doi.org\/10.3390\/curroncol29040233","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,18]]}}}